Pfizer's First Quarter , Profits Blast Past, 2022 Forecast.<br />ABC reports that Pfizer's COVID-19 vaccine and treatment <br />sales helped propel the pharmaceuticals company <br />beyond Wall Street's first quarter expectations. .<br />Pfizer's coronavirus vaccine<br />Comirnaty raked in over $13 billion <br />in sales for the first quarter. .<br />Pfizer's coronavirus vaccine<br />Comirnaty raked in over $13 billion <br />in sales for the first quarter. .<br />The vaccine has remained <br />Pfizer's top selling product <br />for almost the last year. .<br />The drugmaker's pill treatment <br />Paxloid reportedly added an additional <br />$1.5 billion to the company's sales. .<br />ABC reports that Pfizer's, profits grew 61% , in the first quarter. .<br />On May 3, the company posted <br />a net income of $7.86 billion and first <br />quarter adjusted earnings of $1.62 per share. .<br />The results easily exceeded <br />the $1.49 increase predicted <br />by industry analysts. .<br />Compared to the same time last year, <br />the company's revenue skyrocketed 77% , to reach $25.66 billion. .<br />According to ABC, the drugmaker <br />expects the company's total revenue in 2022 <br />to reach between $98 billion and $102 billion. .<br />Pfizer's COVID vaccine launched late<br />in 2020 and quickly became the company's <br />top selling product by the second quarter of 2021.<br />In December of 2021, <br />Pfizer's stock reached an <br />all-time high of $61.71 per share.
